Patents by Inventor Viranga Tillekeratne

Viranga Tillekeratne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ferroptosis-HDAC Inhibitor Hybrid Anticancer Agents
    Publication number: 20240109852
    Abstract: Hybrid molecules having pharmacophores of a ferrotoptosis inducer and an HDAC inhibitor, as well as ferroptosis inducers and HDAC inhibitors, and methods of making and using the same, are described.
    Type: Application
    Filed: August 28, 2023
    Publication date: April 4, 2024
    Applicant: The University of Toledo
    Inventors: Viranga Tillekeratne, Endri Karaj, Shaimaa Sindi, William Taylor
  • Development of a cofilin inhibitor for the treatment of hemorrhagic brain injury-induced neuroinflammation
    Patent number: 11548850
    Abstract: Compounds and methods for inhibiting cofilin activity or reducing total cofilin, improving motor deficits, attenuating LPS-induced microglial activation and inflammation, reducing microglial migration and proliferation, reducing TNF-?, reducing NF-?B, and improving motor deficits in a subject are described.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: January 10, 2023
    Assignee: The University of Toledo
    Inventors: Saleh Alaqel, Viranga Tillekeratne, Zahoor A. Shah
  • Imidazole-based anticancer agents and derivatives thereof, and methods of making and using same
    Patent number: 11098038
    Abstract: Imidazole-based anticancer agents and derivatives thereof, as well as methods of making and methods of using the same, are described. The imidazole-based anticancer agents are HDAC inhibitor compounds having a 1-(1H-imidazol-2-yl)ethan-1-one or 1-(1H-imidazol-2-yl)ethane-1-thione moiety.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: August 24, 2021
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, Ayad Al-Hamashi, Samkeliso Dlamini, Abdulateef Saeed S. Alqahtani, Endri Karaj
  • IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME
    Publication number: 20200385374
    Abstract: Imidazole-based anticancer agents and derivatives thereof, as well as methods of making and methods of using the same, are described. The imidazole-based anticancer agents are HDAC inhibitor compounds having a 1-(1H-imidazol-2-yl)ethan-1-one or 1-(1H-imidazol-2-yl)ethane-1-thione moiety.
    Type: Application
    Filed: August 17, 2018
    Publication date: December 10, 2020
    Applicant: The University of Toledo
    Inventors: Viranga Tillekeratne, Ayad Al-Hamashi, Samkeliso Dlamini, Abdulateef Saeed S. Alqahtani, Endri Karaj
  • Development of a Cofilin Inhibitor for the Treatment of Hemorrhagic Brain Injury-Induced Neuroinflammation
    Publication number: 20200369603
    Abstract: Compounds and methods for inhibiting cofilin activity or reducing total cofilin, improving motor deficits, attenuating LPS-induced microglial activation and inflammation, reducing microglial migration and proliferation, reducing TNF-?, reducing NF-?B, and improving motor deficits in a subject are described.
    Type: Application
    Filed: May 5, 2020
    Publication date: November 26, 2020
    Applicant: The University of Toledo
    Inventors: Saleh Alaqel, Viranga Tillekeratne, Zahoor A. Shah
  • Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
    Patent number: 10392354
    Abstract: Described herein are analogs of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogs having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 27, 2019
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer
    Publication number: 20190023671
    Abstract: Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 24, 2019
    Applicant: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
    Patent number: 10138216
    Abstract: Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: November 27, 2018
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer
    Publication number: 20180009772
    Abstract: Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 11, 2018
    Applicant: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
    Patent number: 9862692
    Abstract: Described herein are analogs of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogs having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: January 9, 2018
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • HDAC inhibitors as anti-cancer agents
    Patent number: 9469656
    Abstract: Largazole analogs, methods of making the same, and methods of using the same, are described.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 18, 2016
    Assignee: The University of Toledo
    Inventors: L. M. Viranga Tillekeratne, Jehad Almaliti, Ayad Al-Hamashi, Pravin Bhansali
  • Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer
    Publication number: 20150344448
    Abstract: Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Application
    Filed: January 21, 2014
    Publication date: December 3, 2015
    Applicant: THE UNIVERSITY OF TOLEDO
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • HDAC Inhibitors as Anti-Cancer Agents
    Publication number: 20150329560
    Abstract: Largazole analogues, methods of making the same, and methods of using the same, are described.
    Type: Application
    Filed: May 14, 2015
    Publication date: November 19, 2015
    Applicant: THE UNIVERSITY OF TOLEDO
    Inventors: L. M. Viranga Tillekeratne, Jehad Almaliti, Ayad Al-Hamashi, Pravin Bhansali
  • Conformationally restrained epothilone analogues as anti-leukemic agents
    Patent number: 8435983
    Abstract: A method for synthesizing anti-leukemic epothilone analogues includes rigidifying a region between the macrolactone ring and the aromatic side-chain. The anti-leukemic compositions are non-naturally occurring epothilone analogue that are rigidified between the macrolactone ring and the aromatic side-chain.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: May 7, 2013
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, Richard A. Hudson, Mamoun Alhamadsheh
  • Epithiolone analogues
    Patent number: 7893268
    Abstract: Epothilone analogues include a molecular scaffold which holds at least one segment of epothilone in a predetermined orientation and which rigidities a region between the macrolactone ring and the aromatic side-chain.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: February 22, 2011
    Assignee: University of Toledo
    Inventors: Viranga Tillekeratne, Richard D. Hudson, Mamoun Alhamadsheh
  • Conformationally Restrained Epothilone Analogues as Anti-Leukemic Agents
    Publication number: 20100324094
    Abstract: A method for synthesizing anti-leukemic epothilone analogues includes rigidifying a region between the macrolactone ring and the aromatic side-chain. The anti-leukemic compositions are non-naturally occurring epothilone analogue that are rigidified between the macrolactone ring and the aromatic side-chain.
    Type: Application
    Filed: March 20, 2008
    Publication date: December 23, 2010
    Applicant: The University of Toledo
    Inventors: Viranga Tillekeratne, Richard A. Hudson, Mamoun Alhamadsheh
  • Epithiolone Analogues
    Publication number: 20090258904
    Abstract: Epothilone analogues include a molecular scaffold which holds at least one segment of epothilone in a predetermined orientation and which rigidities a region between the macrolactone ring and the aromatic side-chain.
    Type: Application
    Filed: July 20, 2006
    Publication date: October 15, 2009
    Inventors: Viranga Tillekeratne, Richard D. Hudson, Mamoun Alhamadsheh